Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07493629 (ISDC-IAD) for Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis, OSAS (Obstructive Sleep Apneas Syndrome), Allergic Bronchopulmonary Aspergillosis (ABPA) is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Immune Status and Disease Control of Inflammatory Airway Diseases (ISDC-IAD) 200
Clinical Trial NCT07493629 (ISDC-IAD) is an observational study for Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis, OSAS (Obstructive Sleep Apneas Syndrome), Allergic Bronchopulmonary Aspergillosis (ABPA) that is recruiting. It started on August 1, 2025 with plans to enroll 200 participants. Led by First Affiliated Hospital of Ningbo University, it is expected to complete by August 1, 2026. The latest data from ClinicalTrials.gov was last updated on March 25, 2026.
Brief Summary
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:
1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.
Participants will:
- Answer questions about their health and symptoms.
- Give blood samples
- Have lung function tests and oth...
Detailed Description
This prospective, single-center observational cohort study aims to comprehensively characterize the immune landscape of patients with chronic airway inflammatory diseases through the application of high-dimensional single-cell technologies.The study plans to enroll approximately 205 to 215 participants, comprising multiple disease groups and matched healthy controls.
A core methodological innovation of this study is...
Show MoreOfficial Title
Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases
Conditions
Airway InflammationChronic Obstructive Pulmonary Disease (COPD)Asthma (Diagnosis)BronchiectasisOSAS (Obstructive Sleep Apneas Syndrome)Allergic Bronchopulmonary Aspergillosis (ABPA)Other Study IDs
- ISDC-IAD
- 2025-156A-01
NCT ID Number
Start Date (Actual)
2025-08-01
Last Update Posted
2026-03-25
Completion Date (Estimated)
2026-08-01
Enrollment (Estimated)
200
Study Type
Observational
Status
Recruiting
Keywords
Airway Inflammatory Diseases
Immunophenotyping
Metabolomics
Cytometry by Time-of-Flight
High-dimensional immune profiling
Immunophenotyping
Metabolomics
Cytometry by Time-of-Flight
High-dimensional immune profiling
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
COPD group The clinical diagnosis was COPD | N/A |
Bronchiectasis group The clinical diagnosis was Bronchiectasis | N/A |
OSAS group The clinical diagnosis was OSAS | N/A |
Asthma group The clinical diagnosis was asthma | N/A |
ABPA group The clinical diagnosis was ABPA | N/A |
Health comparison Healthy person without respiratory disease | N/A |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Peripheral Blood Immune Cell Subset Profiling by Mass Cytometry (CyTOF) | Peripheral blood mononuclear cells (PBMCs) will be analyzed by CyTOF using a 41-marker antibody panel (includingCD4, CD8, HLA-DR, CD25, CD127, CD45RA, CD38, CD66b, IgD,etc.) The outcome will be reported as the relative frequency (%) and absolute counts of defined immune subsets, including T cell subsets (Th1, Th2, Th17, Treg, Tfh, cytotoxic T cells), B cell subsets (naive, memory, B1a, transitional), NK cells, myeloid cells, plasmablasts, monocytes, MDSCs, and granulocytes. Functional phenotypes such as activation (HLA-DR), exhaustion (PD-1), and aging (CD57) will also be quantified. | baseline |
Serum Cytokine Levels by ELISA | Plasma cytokines (e.g., IL-6, TNF-α, IL-10) will be quantified using ELISA. Data will be reported as absolute concentrations (pg/mL) and compared across disease subgroups. | baseline |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Sputum Microbiome Composition by Metagenomic Next-Generation Sequencing (mNGS) | Sputum samples will be analyzed by metagenomic next-generation sequencing (mNGS) to characterize bacterial, fungal, and viral communities. Data will be aggregated as relative abundance (%) of microbial taxa and diversity indices (Shannon, Simpson). | baseline |
Sleep-Disordered Breathing Severity Measured by Polysomnography | For patients with OSAS and snoring, Apnea-Hypopnea Index (AHI), minimum SpO₂, and cumulative time with SpO₂ \< 90% (CT90) will be recorded overnight. Data will be summarized as mean values and categorized into mild, moderate, or severe OSAS. | baseline |
Serum Lipid testing | Including serum total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. | baseline |
Daytime Sleepiness in Obstructive Sleep Apnea Measured by Epworth Sleepiness Scale (ESS) | Epworth Sleepiness Scale (ESS): Evaluates daytime sleepiness severity; higher scores reflect greater impairment.Data will be summarized as mean total scores and categorized into severity levels (normal, mild, moderate, severe). | baseline |
Asthma Control Questionnaire | In the asthma and ABPA research groups, the Asthma Control Questionnaire (ACQ) will be used to evaluate the control of asthma symptoms. ACQ is a validated questionnaire, with each question scoring 0-6 points. The average score will be calculated, with ≤ 0.75 indicating good control, 0.75-1.5 indicating partial control, and\>1.5 indicating uncontrolled. | baseline |
AQLQ (Asthma Quality of Life Questionnaire) Score | The Asthma Quality of Life Questionnaire is used to evaluate the quality of life of asthma patients. The scoring range is 1 - 7 points. The higher the score, the better the quality of life. | Baseline |
Borg rating | The Borg score is used to evaluate the degree of respiratory distress in patients with bronchiectasis, measuring their perceived physical activity or intensity using numbers. Subjective fatigue and respiratory distress are quantified on a 0-10 point scale, with higher scores indicating more severe respiratory distress. | baseline |
FACED Score | FACED Score includes Forced Expiratory Volume in 1 second (FEV1)、Age、 Chronic colonization by Pseudomonas aeruginosa (PA)、Extension (number of pulmonary lobes affected)、Dyspnea (mMRC score).It is used to assess the severity of bronchiectasis. The scoring range is from 0 to 10 points. Grade classification: 0 - 2 points: Mild. 3 - 5 points: Moderate. 6 - 10 points: Severe. | baseline |
CAT(COPD Assessment Test) Score | A tool used in the bronchiectasis group to assist in assessing the severity and quality of life of patients with bronchiectasis. The rating range is 0-10 points. Grade classification: 0-2 points: Mild; 3-5 points: moderate; 6-10 points: severe. | baseline |
SGRQ(St. George's Respiratory Questionnaire)Score | The SGRQ is used to evaluate the quality of life of patients with chronic respiratory diseases. It consists of three parts: symptoms, activities, and impact on daily life. The scoring range is 0 - 100 points. The higher the total score, the poorer the patient's quality of life. | baseline |
mMRC(Modified Medical Research Council Dyspnea Scale)Score | The mMRC Score is used to assess the severity of dyspnoea and is divided into grades 0 - 4. The higher the score, the more severe the dyspnoea. Grade 0: Dyspnoea occurs only during strenuous exercise. Grade 1: Dyspnoea occurs when walking fast on flat ground or climbing a gentle slope. Grade 2: Dyspnoea causes the patient to stop and rest when walking on flat ground. Grade 3: Dyspnoea causes the patient to stop and rest after walking less than 100 metres or for a few minutes on flat ground. Grade 4: The patient is unable to leave home due to dyspnoea, or dyspnoea occurs when dressing or undressing. | baseline |
FEV1(Forced Expiratory Volume in 1 second) | Pulmonary function FEV1 index was evaluated in liters (L). It refers to the volume of air exhaled in the first second by the subject exhaling at the fastest rate after the maximum inspiration. | baseline |
MMEF75/25(Maximal Mid-Expiratory Flow between 75% and 25% of FVC) | MMEF75/25 is measured in liters per minute (L/min). This is the average expiratory flow rate over the course of 75% to 25% of the forced expiratory volume. It is primarily used to assess the function of the small airways. | baseline |
FVC(Forced Vital Capacity) | FVC is measured in liters (L). It is the maximum volume of air that can be exhaled by exhaling forcefully as fast as possible after the maximum inhalation. This indicator reflects the ventilatory function of the lungs. FVC is generally around 3.5 - 5 L in normal adult males and slightly lower in females. FVC can be used to assess the elasticity of the lungs, the patency of the airways, etc. | baseline |
FEV1/FVC(Forced Expiratory Volume in 1 second to Forced Vital Capacity Ratio) | The unit of FEV1/FVC is %. It is mainly used to determine if there is an airflow obstruction. Normally, FEV1/FVC should be greater than 70%. | baseline |
Fractional Exhaled Nitric Oxide (FeNO) Levels Measured by Standardized Analyzer | FeNO will be measured in exhaled air and reported in parts per billion (ppb). Data will be summarized as mean values to reflect airway inflammation. | baseline |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
- Age ≥18 years (≥40 years for COPD patients).
- Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.
- PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 <80% predicted)
- Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.
- Healthy controls: normal lung function, FeNO <20 ppb, total IgE <100 IU/mL, no chronic disease, smoking <10 pack-years, no immunosuppressant use within 3 months.
- Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.
- Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.
- Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)
- Pregnant or lactating women.
- Patients with poor compliance as judged by the investigators.
- Subjects currently participating in other clinical studies.
Study Central Contact
Contact: chao Cao, Doctor, +86-0574-87085233, [email protected]
1 Study Locations in 1 Countries
Zhejiang
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
chao Cao, Doctor, Contact, +86-0574-87089878, [email protected]
Recruiting